Clinical Trial Results - Cancer Currents Blog
Reports on findings from cancer clinical trials, with commentary from leading researchers on how the trial results will affect patient care.
-
In a trial, men who received stereotactic body radiotherapy (SBRT) didn’t have a higher risk of cancer recurrence than men treated with other common radiation therapy regimens that are given over longer periods.
-
In a nearly 1,000-patient trial, treatment with nivolumab (Opdivo) and the chemotherapy regimen AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD and brentuximab (Adcetris). The nivolumab combination also had fewer side effects.
-
A randomized clinical trial comparing two types of surgery in people with localized muscle-invasive bladder cancer found that more extensive surgery removing a larger group of lymph nodes did not improve survival, compared with standard lymph node surgery.
-
In a study of people with advanced lung cancer, palliative care delivered via telehealth was just as effective at improving patients’ quality of life and other measures of well-being as care delivered in person.
-
In a clinical trial, people with advanced cancer and cachexia treated with the experimental drug ponsegromab gained an average of 2 to 6 pounds over 12 weeks, depending on the dose they received. Participants treated with the placebo lost an average of 1 pound over the same time period.
-
Results from a French clinical trial have identified what experts say should now be the recommended initial treatment of advanced leiomyosarcoma. In the trial, the combination of trabectedin (Yondelis) and doxorubicin improved survival by a median of 9 months.
-
Trial participants who stopped imatinib had a more rapid worsening of disease, a shorter time until resistance, and did not live as long as participants who continued the therapy uninterrupted.
-
Scientists have been searching for ways to make immune checkpoint inhibitors work for more patients. In two trials, researchers explored a possible role for JAK inhibitors, which dampen chronic inflammation.
-
Lorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with ALK-positive advanced non-small cell lung cancer, according to new clinical trial results. Treatment with lorlatinib also helped prevent new brain metastases.
-
For people with locally advanced esophageal cancer, a chemotherapy regimen called FLOT is the preferred treatment, according to results from a large clinical trial. People treated with FLOT lived much longer than those treated with the CROSS regimen.